Rocbrutinib: First Approval.

IF 14.7 1区医学 Q1 PHARMACOLOGY & PHARMACY

Drugs Pub Date : 2026-10-15 DOI:10.1007/s40265-026-02393-z

Simon Fung

引用次数: 0

Abstract

Rocbrutinib (; LP-168) is a fourth generation Bruton's tyrosine kinase (BTK) inhibitor with both covalent and non-covalent modes of binding, which allow it to inhibit both wildtype as well as mutant variants of BTK. It is being developed by Lupeng Pharmaceuticals primarily as a treatment for patients with B-cell malignancies. Rocbrutinib received its first approval in June 2026 in China for use in adult patients with mantle cell lymphoma (MCL) that is relapsed or refractory to BTK inhibitors, and who have received ≥ 2 systemic therapies (including BTK inhibitors). This article summarizes the milestones in the development of rocbrutinib leading to its first approval in this indication.

查看原文本刊更多论文

罗鲁替尼：首次批准。

Rocbrutinib （; LP-168）是第四代布鲁顿酪氨酸激酶（BTK）抑制剂，具有共价和非共价结合模式，这使得它可以抑制野生型和突变型BTK。该药物由鲁鹏制药公司开发，主要用于治疗b细胞恶性肿瘤患者。罗鲁替尼于2026年6月在中国获得首次批准，用于BTK抑制剂复发或难治性的成年套细胞淋巴瘤（MCL）患者，并且接受了≥2种全身治疗（包括BTK抑制剂）。本文总结了罗鲁替尼在这一适应症中首次获批的发展里程碑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drugs 医学-毒理学

CiteScore

22.70

自引率

0.90%

发文量

134

审稿时长

3-8 weeks

期刊介绍： Drugs is a journal that aims to enhance pharmacotherapy by publishing review and original research articles on key aspects of clinical pharmacology and therapeutics. The journal includes: Leading/current opinion articles providing an overview of contentious or emerging issues. Definitive reviews of drugs and drug classes, and their place in disease management. Therapy in Practice articles including recommendations for specific clinical situations. High-quality, well designed, original clinical research. Adis Drug Evaluations reviewing the properties and place in therapy of both newer and established drugs. AdisInsight Reports summarising development at first global approval. Moreover, the journal offers additional digital features such as animated abstracts, video abstracts, instructional videos, and podcasts to increase visibility and educational value. Plain language summaries accompany articles to assist readers with some knowledge of the field in understanding important medical advances.